arrow
N

Nada Hamad

st vincent's hospital
H指数:23
被引数:3,092

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

LTB-TREAT: A validated international prognostic model for time to treatment in low tumour burden follicular lymphoma

LTB-TREAT:一种用于低肿瘤负荷滤泡性淋巴瘤治疗时间预测的国际验证性预后模型

2026-08-300
OAAI
A randomized pilot trial comparing anti-thymocyte globulin with anti-thymocyte globulin plus post transplant cyclophosphamide for prophylaxis against acute and chronic graft versus host disease in matched donor hematopoietic cell transplants – a study from the Cell Therapy Transplant Canada/ Australasian Leukemia Lymphoma Group Consortium

一项随机试点试验,比较抗胸腺细胞球蛋白与抗胸腺细胞球蛋白加移植后环磷酰胺对匹配供体造血细胞移植中预防急性和慢性移植物抗宿主病的效果——加拿大细胞治疗移植/澳大利亚白血病淋巴瘤研究集团联盟的研究

2026-08-210
OAAI
Comparison of immunity-boosting regimens for COVID-19 upon initiation of immunosuppressive therapy (CIRCUIT): study protocol for a randomised, controlled clinical trial

比较免疫增强方案对免疫抑制治疗开始时COVID-19的影响(CIRCUIT):随机对照临床试验研究方案

2026-04-240
PRE
The impact of age on survival and excess mortality after autologous hematopoietic cell transplantation in newly diagnosed multiple myeloma patients

年龄对初诊多发性骨髓瘤患者自体造血细胞移植后生存和超额死亡率的影响

2026-01-011
OA
Correction: Non-cryopreserved autologous peripheral blood stem cell transplantation for multiple myeloma and lymphoma in countries with limited resources: practice considerations from the Worldwide Network for Blood and Marrow Transplantation

更正:在资源有限国家中,使用非冷冻保存的自体外周血干细胞移植治疗多发性骨髓瘤和淋巴瘤:来自世界骨髓移植联盟的实践考量

2025-06-300
PRE
Setting up a Chimeric Antigen Receptor T Cell Therapy Program: A Framework for Delivery from the Worldwide Network for Blood & Marrow Transplantation

建立嵌合抗原受体T细胞疗法项目:世界造血与骨髓移植网络交付框架

2025-05-230
PRE
A comparison of Cryopreserved and non-Cryopreserved Peripheral Blood Hematopoietic Stem Cells for Autologous Transplantation in Multiple Myeloma: A study from the Chronic Malignancies Working Party of the EBMT

比较冷冻保存与非冷冻保存的外周血造血干细胞在多发性骨髓瘤自体移植中的应用:EBMT慢性恶性疾病工作组的研究

2025-03-070
PRE
Compassionate access to virus-specific T cells for adoptive immunotherapy over 15 years
2024-12-030
OAAI
Treatment of First Relapse of Multiple Myeloma in Australia and New Zealand (ANZ): Treatment Patterns and Outcomes: An ANZ Myeloma and Related Diseases Registry (ANZ MRDR) Analysis

澳大利亚和新西兰(ANZ)多发性骨髓瘤首次复发后的治疗:治疗模式和结局:一项ANZ骨髓瘤及相关疾病登记研究(ANZ MRDR)分析

BLOOD
IF23.1
2024-11-050
PRE
Body Mass Index and Clinical Associations in Australasian Lymphoma Patients: A Lymphoma and Related Diseases Registry Study

体重指数与澳大利亚及大洋洲淋巴瘤患者的临床关联:一项淋巴瘤及相关疾病登记研究

BLOOD
IF23.1
2024-11-050
PRE
Clinical Practice Recommendations for Hematopoietic Cell Transplantation and Cellular Therapies in Follicular Lymphoma: A Collaborative Effort on Behalf of the American Society for Transplantation and Cellular Therapy and the European Society for Blood and Marrow Transplantation

滤泡性淋巴瘤的造血细胞移植和细胞治疗的临床实践建议: 代表美国移植和细胞治疗学会和欧洲血液和骨髓移植学会的合作努力

2024-09-012
OAAI
Global characteristics and outcomes of autologous hematopoietic stem cell transplantation for newly diagnosed multiple myeloma: A study of the worldwide network for blood and marrow transplantation (WBMT)
2024-08-193
OAAI
Donor types and outcomes of transplantation in myelofibrosis: a CIBMTR study
2024-08-142
OAAI